The Biopharma Patent Cliff: 9 Drugs Losing Exclusivity by the End of 2023

The biopharma industry has been creeping over a patent cliff for months, with several drugs losing their primary patents and more patents expected to expire in the next seven years. This opens the door for new generics to enter the market, lowering drug prices and therefore reducing how much manufacturers can rake in from brand name products.